Clinical benefits of antisense therapy in a phase III trial in patients with CLL.
D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*
D016376:Oligonucleotides, Antisense